MIRA jumps on partnership to develop antidepressant

Mira Pharmaceuticals

05/02/2024 15:56

** Shares of drug developer MIRA Pharmaceuticals  MIRA.O 
rise ~39.3% to $1.29, set to be its biggest one-day gain since
November  
    ** Co has partnered with Pharmaseed, a private clinical
research organization, to evaluate a type of ketamine called
Ketamir-2 to potentially be used as an antidepressant 
    ** Says MIRA and Pharmaseed will conduct studies that
include safety and efficacy evaluation in various animal models
    ** Co expects these studies will position Ketamir for a
marketing application with FDA by the end of 2024
    ** Including session's move, stock down ~79.4% since its IPO
in August

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))